Leber Congenital Amaurosis

Leber Congenital Amaurosis (LCA) is a rare genetic eye disease that affects the retina, the light-sensitive tissue at the back of the eye. Babies born with LCA typically have very poor vision or are completely blind from birth or within the first few months of life. Because their eyes cannot properly detect light and send clear signals to the brain, infants with LCA often develop rapid, involuntary eye movements called nystagmus. They may also frequently rub or poke their eyes, a behavior known as the oculo-digital sign, which is thought to create the sensation of light flashes. LCA is caused by changes (mutations) in one of many different genes that are essential for the normal development and function of the retina. It is usually inherited when both parents carry a copy of the mutated gene and pass it on to their child. The specific gene involved determines how the disease affects the eye and whether the vision loss remains stable or worsens over time. While LCA primarily affects vision, some children may also experience high farsightedness, sensitivity to light, or develop cataracts or a cone-shaped cornea (keratoconus) as they grow. Currently, there is no cure for most types of LCA, and management focuses on supportive care, such as using low-vision aids and providing educational support to help children maximize their remaining sight and adapt to their environment. However, there is hope through ongoing research. A groundbreaking gene therapy called Luxturna has been approved for one specific type of LCA (caused by the RPE65 gene), which can improve vision in eligible patients. Families are encouraged to seek genetic testing to identify the exact cause of their child's LCA, as this information is crucial for understanding the condition and determining if they might benefit from current or future treatments.

Condition category: Retinal Dystrophy

Prevalence: 1 in 30,000 to 1 in 80,000

Inheritance patterns: Autosomal Recessive, X-Linked

Age of onset: Birth to early childhood

Clinical overview: Leber Congenital Amaurosis (LCA) is a group of rare, early-onset, and severe inherited retinal dystrophies that represent the most common genetic cause of blindness in childhood. First described by Theodor Leber in 1869, the condition is characterized by profound visual impairment or complete blindness present at birth or within the first few months of life. Clinically, LCA is defined by a triad of severe vision loss, wandering or pendular nystagmus, and a severely subnormal or non-recordable electroretinogram (ERG), indicating widespread dysfunction of the retinal photoreceptors. The disease is genetically highly heterogeneous, with mutations in nearly 30 different genes identified as causative, accounting for the majority of cases. These genes are involved in various critical retinal functions, including phototransduction, the visual cycle, ciliary transport, and photoreceptor development. Due to this genetic diversity, the clinical presentation, fundus appearance, and rate of disease progression can vary significantly among patients, leading to the classification of LCA into numerous genetic subtypes (e.g., LCA1 through LCA19). The condition is primarily inherited in an autosomal recessive manner. LCA is of significant clinical importance not only because of its severe impact on vision and quality of life but also because it has been at the forefront of pioneering treatments for inherited retinal diseases. It was the first inherited retinal dystrophy for which an FDA-approved gene therapy (voretigene neparvovec-rzyl) became available, specifically for patients with biallelic RPE65 mutations. The OMIM phenotypic series for LCA includes numerous entries, such as 204000 (LCA1) and 204100 (LCA2), reflecting its genetic complexity. The Orphanet number for LCA is ORPHA:65.

Patient and family guide: Leber Congenital Amaurosis (LCA) is a rare genetic eye disease that affects the retina, the light-sensitive tissue at the back of the eye. Babies born with LCA typically have very poor vision or are completely blind from birth or within the first few months of life. Because their eyes cannot properly detect light and send clear signals to the brain, infants with LCA often develop rapid, involuntary eye movements called nystagmus. They may also frequently rub or poke their eyes, a behavior known as the oculo-digital sign, which is thought to create the sensation of light flashes. LCA is caused by changes (mutations) in one of many different genes that are essential for the normal development and function of the retina. It is usually inherited when both parents carry a copy of the mutated gene and pass it on to their child. The specific gene involved determines how the disease affects the eye and whether the vision loss remains stable or worsens over time. While LCA primarily affects vision, some children may also experience high farsightedness, sensitivity to light, or develop cataracts or a cone-shaped cornea (keratoconus) as they grow. Currently, there is no cure for most types of LCA, and management focuses on supportive care, such as using low-vision aids and providing educational support to help children maximize their remaining sight and adapt to their environment. However, there is hope through ongoing research. A groundbreaking gene therapy called Luxturna has been approved for one specific type of LCA (caused by the RPE65 gene), which can improve vision in eligible patients. Families are encouraged to seek genetic testing to identify the exact cause of their child's LCA, as this information is crucial for understanding the condition and determining if they might benefit from current or future treatments.

Symptoms and clinical features: The clinical presentation of Leber Congenital Amaurosis is characterized by severe visual impairment that is evident very early in life. In the early stages, typically presenting at birth or within the first six months, infants demonstrate a profound lack of visual responsiveness. Parents or pediatricians may notice that the infant fails to fixate on or follow objects. A hallmark sign that develops shortly after birth is sensory nystagmus, which consists of rapid, involuntary, wandering, or pendular eye movements resulting from the brain's inability to receive clear visual input. Another classic early behavioral symptom is the Franceschetti's oculo-digital sign, where the child frequently pokes, presses, or rubs their eyes, likely to stimulate the retina mechanically and produce the sensation of light flashes (phosphenes). As the child enters the intermediate stages of childhood, additional visual and ocular symptoms become apparent. Depending on the genetic subtype, patients may exhibit extreme sensitivity to light (photophobia) or, conversely, severe night blindness (nyctalopia). High refractive errors, particularly severe hypermetropia (farsightedness), are very common, though high myopia can also occur. Pupillary responses to light are typically sluggish or near-absent. During this stage, fundus examination, which may have been normal in infancy, often begins to show signs of retinal degeneration, such as vascular attenuation, pigmentary changes, or macular abnormalities. In the advanced stages, progressing into late childhood and adulthood, the visual acuity often continues to decline, sometimes leading to complete loss of light perception. The structural degeneration of the retina becomes more pronounced, with widespread chorioretinal atrophy and classic bone-spicule pigmentation resembling retinitis pigmentosa. Additionally, patients with LCA are at an increased risk of developing secondary ocular complications over time, including keratoconus (a progressive thinning and bulging of the cornea) and early-onset cataracts, which can further compromise any remaining vision. While LCA is primarily an isolated ocular disorder, some genetic mutations associated with LCA can also cause syndromic conditions, meaning systemic features like hearing loss, kidney dysfunction, or neurodevelopmental delays may become evident as the child grows.

Molecular pathology: The molecular pathology of Leber Congenital Amaurosis involves the disruption of various critical pathways essential for the development, function, and survival of retinal photoreceptors (rods and cones) and the retinal pigment epithelium (RPE). The proteins encoded by LCA-associated genes function in several distinct cellular processes, including the phototransduction cascade, the retinoid (visual) cycle, photoreceptor ciliary transport, photoreceptor morphogenesis, and cellular metabolism. Mutations affecting the phototransduction cascade, such as those in GUCY2D (encoding retinal guanylyl cyclase 1) and AIPL1, impair the photoreceptors' ability to convert light into electrical signals. For instance, GUCY2D mutations lead to a failure in replenishing cGMP after light exposure, leaving the photoreceptors in a constant state of hyperpolarization and unable to respond to further light stimuli. Defects in the retinoid cycle, caused by mutations in genes like RPE65 (encoding retinoid isomerohydrolase) and LRAT, prevent the regeneration of 11-cis-retinal, the essential chromophore required for light detection by opsin proteins. This leads to a profound deficiency in visual pigment function and subsequent photoreceptor degeneration. Another major category involves defects in the connecting cilium and intraflagellar transport (IFT) within photoreceptors, associated with genes like CEP290, RPGRIP1, LCA5 (lebercillin), and SPATA7. These proteins are crucial for the trafficking of structural and functional molecules between the inner and outer segments of the photoreceptors. Disruption of this transport system leads to the failure of outer segment formation and rapid photoreceptor cell death. Additionally, mutations in genes like CRB1 affect photoreceptor morphogenesis and the maintenance of adherens junctions between photoreceptors and Müller glia, resulting in disorganized retinal architecture and progressive degeneration.

Genetics: Leber Congenital Amaurosis is genetically heterogeneous, with mutations in at least 29 different genes identified to date, accounting for 70% to 80% of all cases. The condition is predominantly inherited in an autosomal recessive manner, meaning an affected individual must inherit two mutated copies of the causative gene, one from each parent. Rarely, mutations in certain genes, such as CRX and IMPDH1, can cause LCA through an autosomal dominant inheritance pattern, where a single mutated copy is sufficient to cause the disease. The most frequently mutated genes in LCA include CEP290 (accounting for approximately 15% of cases), GUCY2D (12-20%), CRB1 (10%), and RPE65 (5-10%). Other known causative genes include AIPL1, SPATA7, LCA5, RPGRIP1, NMNAT1, RD3, RDH12, LRAT, TULP1, KCNJ13, GDF6, IFT140, IQCB1, CLUAP1, PRPH2, ALMS1, CABP4, DTHD1, OTX2, and USP45. The genetic heterogeneity reflects the diverse roles these genes play in retinal development and function. Genotype-phenotype correlations are increasingly recognized in LCA. For example, patients with GUCY2D mutations often have severely reduced vision from birth but may maintain a relatively normal fundus appearance for years and retain some rod function. In contrast, RPE65 mutations are associated with a specific "blond" fundus appearance, early nyctalopia, and progressive retinal degeneration, but patients may have slightly better initial visual acuity. CRB1 mutations frequently present with thickened retinas and preservation of para-arteriolar retinal pigment epithelium. Identifying the specific genetic mutation is crucial not only for confirming the diagnosis but also for predicting the disease course and determining eligibility for targeted therapies.

Diagnostic evaluation: The clinical diagnosis of Leber Congenital Amaurosis (LCA) relies on a combination of early-onset severe visual impairment, sluggish pupillary responses, and characteristic electrophysiological findings. Fundoscopy in infants may initially appear normal but typically progresses to show variable changes depending on the genetic subtype. These changes can include vascular attenuation, bone-spicule pigmentation, nummular pigmentation, macular coloboma-like lesions, or a "blond" fundus appearance with white punctate lesions (often seen in RPE65 mutations). Optical coherence tomography (OCT) is crucial for assessing retinal architecture, which can range from relatively preserved outer retinal structures (e.g., in GUCY2D mutations) to severe disorganization and thinning. Electroretinography (ERG) is the cornerstone of LCA diagnosis. In affected infants, the ERG is typically severely subnormal or completely non-recordable under both scotopic (dark-adapted) and photopic (light-adapted) conditions, reflecting profound dysfunction of both rod and cone photoreceptors. This profound ERG reduction is essential to differentiate LCA from other early-onset retinal dystrophies where some ERG function might be preserved initially. Molecular genetic testing is required to confirm the diagnosis and identify the specific genetic subtype, which is critical for prognosis and potential gene therapy eligibility. Testing usually involves multi-gene panels or whole-exome sequencing targeting the known LCA-associated genes. Differential diagnosis includes other causes of early childhood blindness such as severe early-onset retinitis pigmentosa, achromatopsia, congenital stationary night blindness, and syndromic conditions like Joubert syndrome, Senior-Løken syndrome, and peroxisomal disorders, which may initially present with isolated retinal findings before systemic features become apparent.

Differential diagnosis: Differential diagnosis of Leber congenital amaurosis includes: (1) Early-onset retinitis pigmentosa — later onset (after age 1), less severe initial presentation. (2) Congenital stationary night blindness — nonprogressive, better preserved ERG responses. (3) Achromatopsia — severe photophobia, absent cone responses but preserved rod ERG. (4) Joubert syndrome — LCA with molar tooth sign on brain MRI, hypotonia, and breathing abnormalities. (5) Senior-Løken syndrome — LCA with nephronophthisis (progressive renal failure). (6) Peroxisomal disorders (Zellweger spectrum) — retinal dystrophy with hepatic dysfunction, hypotonia, and craniofacial dysmorphism. (7) Congenital infection (TORCH) — retinal findings with microcephaly, intracranial calcifications; serologic confirmation. (8) Cortical visual impairment — normal fundus and ERG with abnormal visual evoked potentials. (9) Delayed visual maturation — transient visual inattention that resolves by 6 months.

Natural history: The natural history of Leber Congenital Amaurosis is characterized by severe visual impairment that is typically present at birth or becomes apparent within the first six months of life. The initial presentation often includes a lack of visual responsiveness, wandering eye movements, and the development of pendular nystagmus. The progression of visual loss varies significantly depending on the underlying genetic mutation. In some genetic subtypes, such as those associated with GUCY2D mutations, visual acuity may be profoundly reduced from birth but remains relatively stable over the first few decades of life. In contrast, other forms, such as those caused by RPE65 or RDH12 mutations, may present with slightly better initial vision but undergo a progressive and relentless decline, leading to complete blindness by early adulthood. The structural degeneration of the retina, as observed on fundoscopy and OCT, also progresses over time, often evolving from a relatively normal appearance in infancy to widespread chorioretinal atrophy, pigmentary changes, and macular degeneration in later stages. Prognostic factors are heavily tied to the specific genetic etiology. While the overall prognosis for vision is poor, identifying the causative gene can provide families with a more accurate expectation of the disease trajectory. Furthermore, the natural history of certain subtypes, particularly RPE65-associated LCA, has been altered by the advent of gene therapy, which can stabilize or improve visual function if administered before extensive retinal degeneration has occurred.

Management and treatment research: ### Current management and supportive care Management of Leber congenital amaurosis (LCA) is individualized and remains important for every genetic subtype, including people who may be eligible for a targeted treatment or research study. Care may include: - **Regular care with an inherited retinal disease specialist** to monitor vision and identify treatable concerns, such as refractive errors, cataracts, or keratoconus (progressive thinning and bulging of the cornea). - **Glasses or contact lenses** for refractive errors. Tinted lenses and other strategies may help some people with light sensitivity (photophobia). - **Low-vision rehabilitation**, including magnifiers, electronic visual aids, screen-reader technology, and training to use remaining vision effectively. - **Orientation and mobility training**, occupational therapy, and school-based supports for children with visual impairment. - **Genetic testing and genetic counseling** to identify the responsible gene, clarify inheritance, inform family planning, and determine whether an approved treatment or gene-specific study may be relevant. ### Approved therapy for RPE65-associated retinal disease **Voretigene neparvovec-rzyl (Luxturna)** is an FDA-approved gene therapy for people with confirmed disease-causing variants in both copies of the **RPE65** gene. Biallelic *RPE65* variants can cause an LCA subtype sometimes called LCA2. Luxturna is a gene-augmentation therapy. During retinal surgery, an adeno-associated virus (AAV) vector delivers a working copy of *RPE65* to retinal pigment epithelium cells through a **subretinal injection**. Eligible individuals must have sufficient viable retinal cells. Treatment may improve functional vision, including the ability to navigate in dim light. It does not restore normal vision or replace retinal cells that have already been lost. Long-term follow-up of treated participants is ongoing (NCT03602820). ### Investigational therapies The following approaches are experimental and are not approved treatments. Trial availability and eligibility can change. #### Gene-augmentation therapies Gene augmentation uses a vector, often a modified virus, to deliver a functional copy of a gene to retinal cells. - **ATSN-101** is an AAV5 gene-augmentation therapy for LCA caused by disease-causing variants in both copies of **GUCY2D** (LCA1). It is delivered by subretinal injection. Its Phase 1/2 study is active but not recruiting (NCT03920007). - **PUMCH-E101** is an early-stage AAV gene-augmentation therapy for **RDH12**-associated retinal disease. It is delivered by subretinal injection, and its study is recruiting (NCT06749639). - **OPGx-RDH12-1001** is another subretinal gene-augmentation approach for **RDH12**-associated LCA-related inherited retinal degeneration. Its Phase 1/2 study is not yet recruiting (NCT07681778). - **LX101** is an AAV gene-augmentation therapy for **LCA5**-associated LCA. Its Phase 1/2 study has been completed (NCT05882006). - **OCU400** is being studied in a Phase 1/2 trial that includes people with retinitis pigmentosa and LCA. This study is active but not recruiting (NCT05203939). #### RNA and gene-editing approaches for CEP290-associated LCA - **Sepofarsen (QR-110)** is an antisense oligonucleotide—an RNA-based medicine designed to correct abnormal RNA splicing. It is intended for LCA10 caused by the common **CEP290 IVS26** mutation and is administered by intravitreal injection (an injection into the eye). The Phase 3 HYPERION study is recruiting (NCT06891443). - **EDIT-101** is an investigational in vivo CRISPR/Cas9 gene-editing treatment for the *CEP290* IVS26 mutation. It uses an AAV5 vector to remove the mutation-containing region with the goal of restoring normal RNA splicing in photoreceptors. Its early-phase study is NCT03872479; the current study status is not available in the provided trial data. ### Considering a clinical trial Clinical-trial eligibility depends on the genetic diagnosis, retinal findings, age, location, and other health factors. Genetic confirmation is usually essential for gene-specific studies. Registries and natural-history studies may also help families learn about research opportunities. Examples include the Inherited Retinal Degenerative Disease Registry (NCT02435940) and the Rare Disease Patient Registry and Natural History Study at Sanford Health (NCT01793168).

Outlook: The prognosis for visual function in Leber Congenital Amaurosis is generally poor, as it is one of the most severe forms of inherited retinal dystrophy. Most individuals with LCA experience profound visual impairment or legal blindness from infancy, with visual acuity often ranging from 20/200 to no light perception. The specific trajectory of the disease—whether vision remains stable at a very low level or progressively deteriorates to complete blindness—is highly dependent on the underlying genetic mutation. For example, patients with GUCY2D mutations may have stable, albeit poor, vision, while those with RDH12 or RPE65 mutations typically experience progressive retinal degeneration and worsening vision over time. Quality of life considerations are paramount for individuals with LCA and their families. The profound early vision loss necessitates comprehensive early intervention, including specialized educational support, orientation and mobility training, and the use of low-vision aids and adaptive technologies. While the visual prognosis is severe, the advent of targeted gene therapies, such as the approved treatment for RPE65-associated LCA, has introduced the potential to alter the disease course and improve visual outcomes for specific genetic subtypes, offering hope for enhanced independence and quality of life.

Epidemiology: Leber Congenital Amaurosis is a rare genetic disorder with an estimated prevalence ranging from 1 in 33,000 to 1 in 81,000 live births worldwide. It is recognized as one of the most common causes of inherited blindness in childhood, accounting for approximately 5% of all inherited retinal dystrophies and up to 20% of children attending schools for the blind. The condition affects males and females equally, with no significant sex predilection. While LCA occurs across all ethnic groups, the frequency of specific genetic mutations can vary geographically and is often higher in populations with high rates of consanguinity, given its predominantly autosomal recessive inheritance pattern.

Selected references: 1. Chacon-Camacho OF, Zenteno JC. Review and update on the molecular basis of Leber congenital amaurosis. World J Clin Cases. 2015;3(2):112-124. PMID: 25685757 2. Kumaran N, Moore AT, Weleber RG, Michaelides M. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. Br J Ophthalmol. 2017;101(9):1147-1154. PMID: 28689169 3. Huang CH, Yang CM, Yang CH, Hou YC, Chen TC. Leber's Congenital Amaurosis: Current Concepts of Genotype-Phenotype Correlations. Genes (Basel). 2021;12(8):1261. PMID: 34440435 4. Chung DC, Traboulsi EI. Leber congenital amaurosis: clinical correlations with genotypes, gene therapy trials update, and future directions. J AAPOS. 2009;13(6):587-592. PMID: 20006824 5. Perrault I, Rozet JM, Gerber S, et al. Leber congenital amaurosis. Mol Genet Metab. 1999;68(2):200-208. PMID: 10527670 6. Weleber RG, Francis PJ, Trzupek KM, Beattie C. Leber Congenital Amaurosis. 2004 Jul 7 [Updated 2013 May 2]. In: Adam MP, Ardinger HX, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. PMID: 20301475